Anson Funds Management’s Immunocore IMCR Stock Holding History

Anson Funds Management’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,000	Closed	-$426K	–	297
2021 Q1	$426K	Buy	+10,000	New	+$445K	0.05%	227

Other funds holding IMCR

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Bain Capital Public Equity Management II Boston, Massachusetts $62.1M AUM 25.46% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Anson Funds Management's IMCR Position: Q2 2021 in Review

Anson Funds Management sold out of Immunocore (IMCR) in Q2 2021, closing a stake of 10,000 shares — an estimated $426K sold.

Anson Funds Management first reported a position in IMCR in Q1 2021 and held it in 1 quarter. The position peaked at $426K in Q1 2021. 45 funds tracked by Wall St. Rank hold IMCR as of Q2 2021.

Anson Funds Management reported no remaining Immunocore position as of Q2 2021 after selling out during the quarter.
Anson Funds Management sold 10,000 Immunocore shares in Q2 2021, an estimated $426K.
Anson Funds Management first reported a position in Immunocore in Q1 2021 and held it in 1 quarter.
Anson Funds Management's Immunocore position peaked at $426K in Q1 2021.
45 funds tracked by Wall St. Rank held Immunocore as of Q2 2021.

Based on Anson Funds Management's 13F filing for Q2 2021, filed 13 Aug 2021.